Danaher agreed to acquire Masimo for roughly $10 billion to expand its diagnostics and acute‑care footprint, signaling renewed M&A activity in medical device and hospital diagnostics. Danaher framed the transaction as a move to integrate continuous clinical data and scale solutions used in acute settings. The deal follows broader consolidation trends as larger industrial health conglomerates seek to bulk up in diagnostics, monitoring and perioperative technologies. Financial and strategic analysts noted the deal could reshape competitive dynamics for bedside monitoring and push further platform integration across hospital systems. Regulatory reviews and integration execution will determine the near‑term value creation; the purchase highlights investor focus on diagnostics as a durable growth avenue inside healthcare.